Analyzing...
Loading company...
No significant concerns identified
Nothing flagged for monitoring
“Operates in Pharmaceuticals — Formulations & API.”
₹1,716 Cr revenue.
COGS 56.1%, employees 15.0%.
| KPI | Company | Sector Median |
|---|---|---|
| ROE | 25.1%▲ | 10.5% |
| ROCE | 32.9%▲ | 13.8% |
| Net Margin | 9.1%▲ | 8.7% |
| EBITDA Margin | 14.3%▼ | 16.0% |
| Debt To Equity | 0.00x▼ | 0.21x |
Revenue segment breakdown not available.
| (₹ Cr) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | ₹1,716 Cr +32.5% | ₹1,296 Cr +29.2% | ₹1,003 Cr +24.5% | ₹806 Cr -1.0% | ₹814 Cr -2.2% | ₹832 Cr +14.2% | ₹728 Cr |
| Other Income | ₹41 Cr +16.8% | ₹35 Cr +33.3% | ₹26 Cr +76.9% | ₹15 Cr +14.9% | ₹13 Cr -1.1% | ₹13 Cr -20.2% | ₹16 Cr |
| Total Income | ₹1,757 Cr +32.1% | ₹1,330 Cr +29.3% | ₹1,029 Cr +25.4% | ₹820 Cr -0.7% | ₹826 Cr -2.2% | ₹845 Cr +13.5% | ₹745 Cr |
| COGS | ₹963 Cr +62.0% | ₹595 Cr +65.2% | ₹360 Cr +15.4% | ₹312 Cr +5.8% | ₹295 Cr -3.4% | ₹305 Cr +32.1% | ₹231 Cr |
| ₹1,504 Cr +33.4% | ₹1,127 Cr +31.9% | ₹855 Cr +15.9% | ₹737 Cr +5.4% | ₹699 Cr -4.3% | ₹731 Cr +8.8% | ₹672 Cr | |
| Profit Before Tax | ₹156 Cr -28.8% | ₹220 Cr +63.7% | ₹134 Cr +61.5% | ₹83 Cr -34.7% | ₹127 Cr +11.5% | ₹114 Cr +56.8% | ₹73 Cr |
| Exceptional Items | (₹97 Cr) ↓ Decline | ₹16 Cr ↑ Recovery | (₹40 Cr) | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr |
| ₹41 Cr -30.0% | ₹58 Cr +66.7% | ₹35 Cr +62.3% | ₹21 Cr -36.5% | ₹34 Cr -19.1% | ₹42 Cr +129.1% | ₹18 Cr | |
| Net Profit | ₹116 Cr -28.3% | ₹162 Cr +62.7% | ₹99 Cr +61.2% | ₹62 Cr -34.0% | ₹93 Cr +29.2% | ₹72 Cr +32.6% | ₹54 Cr |
| Other Comprehensive Income | (₹1 Cr) ↓ Decline | ₹1 Cr ↑ Recovery | (₹3 Cr) -50.9% | (₹2 Cr) ↓ Decline | ₹3 Cr ↑ Recovery | (₹5 Cr) -719.7% | (₹0.60 Cr) |
| EPS | ₹46.30 | ₹64.60 | ₹39.72 | ₹24.64 | ₹37.32 | ₹28.88 | ₹21.78 |
| Diluted Shares | ₹3 Cr | ₹3 Cr | ₹3 Cr | ₹3 Cr | ₹3 Cr | ₹3 Cr | ₹3 Cr |
No related party data available for this company.
This section will be populated when data becomes available.
No earnings call transcripts available.
AstraZeneca Pharma India Limited has informed the Exchange about General Updates
AstraZeneca Pharma India Limited has informed the Exchange about Resignation of Director/KMP/SMP
AstraZeneca Pharma India Limited has informed the Exchange about General Updates
AstraZeneca Pharma India Limited has informed the Exchange about General Updates
AstraZeneca Pharma India Limited has informed the Exchange about Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company
AstraZeneca Pharma India Limited has informed the Exchange about General Updates
AstraZeneca Pharma India Limited has informed the Exchange about General Updates
AstraZeneca Pharma India Limited has informed the Exchange regarding the Amendment to AOA/MOA of the company.
AstraZeneca Pharma India Limited has informed the Exchange regarding Proceedings of Postal Ballot. Further, the company has submitted the Exchange a copy of Srutinizers report along with voting result...
AstraZeneca Pharma India Limited has submitted the Exchange a copy Srutinizers report of Postal Ballot. Further, the company has informed the Exchange regarding voting results.
AstraZeneca Pharma India Limited has informed the Exchange about General Updates
AstraZeneca Pharma India Limited has informed the Exchange about General Updates
AstraZeneca Pharma India Limited has informed the Exchange about General Updates
AstraZeneca Pharma India Limited has informed the Exchange regarding Notice of Postal Ballot
AstraZeneca Pharma India Limited has informed the Exchange about Copy of Newspaper Publication
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.